GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gilead Sciences (GILD) is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 available. The stock has solid fundamentals, improving earnings, supportive analyst sentiment, and meaningful long-term catalysts in HIV and pipeline expansion. I would buy it now rather than wait for a perfect pullback.
GILD is trading pre-market at 130.6, just below its pivot at 133.148 and above S1 at 128.518. Momentum is neutral-to-slightly weak in the very short term: MACD histogram is negative at -0.639, RSI_6 is 40.759, and moving averages are converging, which suggests consolidation rather than a strong breakout. The price is not extended, and the setup looks like a reasonable entry zone for a long-term buyer. The stock trend data suggests near-term weakness is possible, but the one-month outlook remains constructive.
Recent news is constructive: Gilead's FDA-accepted NDA for a combination HIV treatment could support future product growth, and the company continues to lead the HIV market. Analysts have also turned more positive, with multiple target increases from Citi, Morgan Stanley, Truist, Jefferies, Mizuho, UBS, and Cantor. Long-term catalysts include HIV franchise durability, potential launch momentum for Yeztugo, and pipeline progress such as long-acting HIV therapies. Dividend support also makes the stock attractive for long-term holders.
The stock trend estimate points to possible short-term downside over the next day and week. Some analysts still view valuation as rich or remain only neutral, and policy headlines around U.S. drug pricing remain a sector overhang. However, insider and hedge fund activity are neutral rather than negative.
In Q4 2025, Gilead showed healthy growth: revenue rose to $7.925B, up 4.70% YoY, net income increased 22.43% YoY to $2.183B, EPS rose 25.18% YoY to $1.74, and gross margin improved to 79.51%. This is a strong quarter, with earnings growing faster than revenue, which supports quality and operating leverage.
Analyst sentiment is clearly positive overall. Recent targets were raised by Citi to $165, Morgan Stanley to $175, Truist to $155, RBC to $123, Jefferies initiated at $180, Mizuho to $170, UBS to $175, Baird to $145, and Cantor to $155. The majority of ratings are Buy/Overweight/Outperform, while only Barclays is more cautious with Equal Weight and valuation concerns. Wall Street’s pros view GILD as a high-quality large-cap biotech with strong margins, limited near-term patent risk, and improving pipeline optionality; the main con is that some believe the stock is already expensive.
